Other than the completed studies mentioned above, pinometostat is also undergoing clinical evaluation in combination with azacytidine in subjects with R/R, or newly diagnosed AML leukemia with 11q23 rearrangement (Phase 1/2 Studies, NCT03701295, status recruiting) and a Phase 1b/2 investigation in combination with standard induction chemotherapy in patients with newly diagnosed AML with MLL rearrangement (NCT03724084, status – recruiting). This evidence concerns the gene KMT2A and acute myeloid leukemia.